Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.

Q1 Medicine
Skin therapy letter Pub Date : 2016-01-01
B Sofen, G Prado, J Emer
{"title":"Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.","authors":"B Sofen,&nbsp;G Prado,&nbsp;J Emer","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Dyschromia is a leading cause for cosmetic consultation, especially in those with diverse skin types (mixture of ethnicities) and with the rise of non-core and untrained physicians performing cosmetic procedures. Melasma and post-inflammatory hyperpigmentation (PIH) account for the majority of cases and are characterized by pigmented macules and patches distributed symmetrically in sun-exposed areas of the forehead, cheeks, and chin in melasma, and irregularly in areas of inflammation or an inciting traumatic event with PIH. Treatment is challenging and focused on a variety of mechanisms to stop, hinder, and/or prevent steps in the pigment production (melanocytic hyperactivity) process, breaking down deposited pigment for internal removal or external release, exfoliating cells to enhance turnover, and decreasing inflammation. Topical lightening therapy in combination with sun protection is essential for potential improvement. The most commonly prescribed and researched topical lightening agents are hydroquinone (HQ), azelaic acid (AzA), and retinoids - although only HQ and a triple combination cream (Tri-Luma®; fluocinolone acetonide 0.01%, HQ 4%, tretinoin 0.05%) are US FDA-approved for \"bleaching of hyperpigmented skin\" (HQ) and \"melasma\" (Tri-Luma®). Numerous non-HQ brightening/lightening agents, including antioxidant and botanical cosmeceuticals, have recently flooded the market with improvements that claim less irritant potential, as well as avoiding the stigmata associated with HQ agents such as carcinogenesis and cutaneous ochronosis. Combining topical therapy with procedures such as chemical peels, intense pulsed light (IPL), fractional non-ablative lasers or radiofrequency, pigment lasers (microsecond, picosecond, Q-switched), and microneedling, enhances results. With proper treatment, melasma can be controlled, improved, and maintained; alternatively, PIH can be cured in most cases. Herein, we review treatments for both conditions and provide an opinion on proper management for enhanced results. </p>","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"21 1","pages":"1-7"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin therapy letter","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Dyschromia is a leading cause for cosmetic consultation, especially in those with diverse skin types (mixture of ethnicities) and with the rise of non-core and untrained physicians performing cosmetic procedures. Melasma and post-inflammatory hyperpigmentation (PIH) account for the majority of cases and are characterized by pigmented macules and patches distributed symmetrically in sun-exposed areas of the forehead, cheeks, and chin in melasma, and irregularly in areas of inflammation or an inciting traumatic event with PIH. Treatment is challenging and focused on a variety of mechanisms to stop, hinder, and/or prevent steps in the pigment production (melanocytic hyperactivity) process, breaking down deposited pigment for internal removal or external release, exfoliating cells to enhance turnover, and decreasing inflammation. Topical lightening therapy in combination with sun protection is essential for potential improvement. The most commonly prescribed and researched topical lightening agents are hydroquinone (HQ), azelaic acid (AzA), and retinoids - although only HQ and a triple combination cream (Tri-Luma®; fluocinolone acetonide 0.01%, HQ 4%, tretinoin 0.05%) are US FDA-approved for "bleaching of hyperpigmented skin" (HQ) and "melasma" (Tri-Luma®). Numerous non-HQ brightening/lightening agents, including antioxidant and botanical cosmeceuticals, have recently flooded the market with improvements that claim less irritant potential, as well as avoiding the stigmata associated with HQ agents such as carcinogenesis and cutaneous ochronosis. Combining topical therapy with procedures such as chemical peels, intense pulsed light (IPL), fractional non-ablative lasers or radiofrequency, pigment lasers (microsecond, picosecond, Q-switched), and microneedling, enhances results. With proper treatment, melasma can be controlled, improved, and maintained; alternatively, PIH can be cured in most cases. Herein, we review treatments for both conditions and provide an opinion on proper management for enhanced results.

黄褐斑和炎症后色素沉着:管理更新和专家意见。
肤色障碍是美容咨询的主要原因,特别是在那些不同皮肤类型(种族混合)的人群中,以及非核心和未经培训的医生进行美容手术的兴起。黄褐斑和炎症后色素沉着(PIH)占大多数病例,其特征是色素斑和斑块对称地分布在黄褐斑的前额、脸颊和下巴的阳光照射区域,而在炎症区域或PIH的刺激性创伤事件中不规则地分布。治疗是具有挑战性的,并且集中于多种机制来阻止、阻碍和/或阻止色素生成(黑素细胞过度活跃)过程中的步骤,分解沉积的色素以内部去除或外部释放,去角质细胞以增强周转,并减少炎症。局部光照治疗结合防晒对潜在的改善是必不可少的。最常用的处方和研究的局部美白剂是对苯二酚(HQ),二氮二酸(AzA)和类维生素a -尽管只有对苯二酚和三重组合霜(Tri-Luma®;醋酸氟西诺酮(0.01%,HQ 4%,维甲酸0.05%)是美国fda批准用于“漂白色素沉着皮肤”(HQ)和“黄褐斑”(Tri-Luma®)的药物。包括抗氧化剂和植物药妆在内的许多非HQ亮白/亮白剂最近充斥着市场,它们声称具有更少的刺激潜力,并避免了与HQ剂相关的斑痕,如致癌和皮肤衰老。将局部治疗与化学换肤、强脉冲光(IPL)、部分非烧蚀激光或射频、色素激光(微秒、皮秒、q开关)和微针等程序相结合,可以提高效果。治疗得当,黄褐斑可得到控制、改善和维持;另外,在大多数情况下,PIH可以治愈。在此,我们回顾了这两种情况的治疗方法,并提供了适当的管理意见,以提高结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Skin therapy letter
Skin therapy letter Medicine-Medicine (all)
CiteScore
2.80
自引率
0.00%
发文量
0
期刊介绍: The premier international journal on the latest advances, techniques and practice in conservation and restoration from around the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信